Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good performance status and could be candidates for further therapy. An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients. Methods We did this trial at 114 centres in 16 countries. Patients with documented metastatic colorectal cancer and progression during or within 3 months after the last standard therapy were randomised (in a 2:1 ratio; by computer-generated randomisation list and interactive voice response system; preallocated block design (block size six); stratified by previous treatment with VEGF-targeting drugs, time from diagnosis of metastatic disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 weeks of each 4 week cycle. The primary endpoint was overall survival. The study sponsor, participants, and investigators were masked to treatment assignment. Efficacy analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT01103323. Findings Between April 30, 2010, and March 22, 2011, 1052 patients were screened, 760 patients were randomised to receive regorafenib (n=505) or placebo (n=255), and 753 patients initiated treatment (regorafenib n=500; placebo n=253; population for safety analyses). The primary endpoint of overall surv…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [15]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [15]
In the citing paper
“The efficacy and safety of Regorafenib are evaluated on the basis of a CORRECT study [98].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [98]
In the citing paper
“Median overall survival was improved in the regorafenib group compared with placebo (6.4 months versus 5.0 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [58]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
Van Cutsem, E., Nordlinger, B., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq222 · Cited by 479
Self-citationRegorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
Strumberg, D., Scheulen, M. E., Schultheis, B., Richly, H., Frost, A., Büchert, M., Christensen, O., Jeffers, M., Heinig, R., Boix, O., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.153 · Cited by 249
Schmoll, H.-J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5355 · Cited by 213
Self-citationHecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K., Berg, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 178
Self-citationVan Cutsem, E., Bajetta, E., Valle, J., Köhne, C.-H., Randolph Hecht, J., Moore, M., Germond, C., Berg, W., Chen, B.-L., Jalava, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5436 · Cited by 163
Self-citation
Cited by
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
“The estimates of OS at 1- and 2-years were 76% and 64%, respectively, which is markedly higher than expected based on the advanced state of disease in this cohort (21).”
BackgroundSelf-citationDekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citation
Metadata
- Authors
- Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., Adenis, A., Tabernero, J., Yoshino, T., Lenz, H.-J., Goldberg, R. M., Sargent, D. J., Cihon, F., Cupit, L., Wagner, A., & Laurent, D.
- Affiliations
- Mayo Clinic (US)
- KU Leuven (BE)
- Ospedale Policlinico San Martino (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Cliniques Universitaires Saint-Luc (BE)
- Institut Sainte Catherine (FR)
- Università Cattolica del Sacro Cuore (IT)
- Centre Oscar Lambret (FR)
- Universitat Autònoma de Barcelona (ES)
- National Cancer Center Hospital East (JP)
- USC Norris Comprehensive Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Cutsem, Eric Van
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 381
- Issue
- 9863
- Pages
- 303-312
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2147834058
- Semantic Scholar
- 3946becddb85f70009ea8fffb1e1925d19bf0639
- Cited by
- 2,895
- References
- 17
- Citations by year
- 2026: 144 · 2025: 210 · 2024: 260 · 2023: 216 · 2022: 212 · 2021: 211 · 2020: 218 · 2019: 239 · 2018: 195 · 2017: 222 · 2016: 197 · 2015: 234 · 2014: 204 · 2013: 123
- FWCI
- 89.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Funders
- Bayer Fund
- Bayer HealthCare
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, regorafenib, multikinase inhibitor, second-line therapy, best supportive care, overall survival, hand-foot skin reaction, treatment-related adverse events, CORRECT trial, oral anticancer drugs, diarrhea, neutropenia
- MeSH terms
- Aged, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Phenylurea Compounds, Pyridines, Colorectal Neoplasms, Survival Rate, Disease-Free Survival, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61900-x
- The paper
- Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., Adenis, A., Tabernero, J., Yoshino, T., Lenz, H.-J., Goldberg, R. M., Sargent, D. J., Cihon, F., Cupit, L., Wagner, A., & Laurent, D. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(12)61900-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.